Pharma FDA panel questions Roche’s Tecentriq-Abraxane combo in breast cancer, but votes to keep approval in place for now
Looks like Roche is now under pressure from all corners. There is this pressure from the FDA to provide better data and of course, the attack on their market share by biosims and the expectation of shareholders to maintain revenue growth.
Same goes for Merck and BMS.
Pharma FDA panel questions Roche’s Tecentriq-Abraxane combo in...
-
- There are more pages in this discussion • 14,583 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.7¢ | $2.298M | 47.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1925982 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3452098 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |